Prostate biopsy and prostate cancer management in patients with haemophilia: The experience of French Haemophilia Treatment Centres.
biopsy
bleeding complications
haemophilia
prostate cancer
surgery
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
18
01
2022
received:
03
11
2021
accepted:
26
01
2022
pubmed:
25
2
2022
medline:
14
5
2022
entrez:
24
2
2022
Statut:
ppublish
Résumé
Data are limited on prostate cancer (PC) management in patients with haemophilia (PWH). To describe PC screening and diagnosis, treatment modalities and bleeding complications in a group of unselected PWH followed at French Haemophilia Treatment Centres (HTCs) PATIENTS AND METHODS: PC screening, management and bleeding complications were retrospectively investigated at 14 French HTCs between 2003 and 2018. Among> 1549 > 50-year-old PWHs, 73 (4.7%) underwent PC screening (median age 71.1 years; 67/6 HA/HB, 17/56 severe-moderate/mild). At diagnosis, haematuria was infrequent. Prophylaxis was administered during 76/86 (88%) prostate biopsies (PB) (n = 67 clotting factor concentrates, CFC; n = 9 desmopressin; n = 17 associated with tranexamic acid, TA). Bleeding (11/86, 12.8%) occurred mainly post-prophylaxis (median delay: 7 days): haematuria (9/11, 81.8%), and rectal bleeding (2/11, 18.2%) including one major (1.2%). PC was confirmed in 50/86 PB and in two prostatectomy specimens (total n = 50 patients, n = 6 with only active surveillance). Surgery (n = 28/44 patients) was managed with CFC. Fifteen patients had radiotherapy/brachytherapy, 10 had hormone therapy; CFC-based prophylaxis was only prescribed for brachytherapy (n = 2). Major bleedings occurred in 3/28 (10.7%) and 2/15 (13.3%) patients who underwent surgery and radio/brachytherapy, respectively. No bleeding risk factor was found. Our data indicate that PB requires prophylaxis for atleast 7 days, using CFC, desmopressin or TA in function of haemophilia severity. PC surgery should be considered at high bleeding risk. Long-term post-procedural CFC or oral TA could be discussed. Radiotherapy/brachytherapy also should be managed with prophylaxis (CFC or TA).
Sections du résumé
BACKGROUND
BACKGROUND
Data are limited on prostate cancer (PC) management in patients with haemophilia (PWH).
AIM
OBJECTIVE
To describe PC screening and diagnosis, treatment modalities and bleeding complications in a group of unselected PWH followed at French Haemophilia Treatment Centres (HTCs) PATIENTS AND METHODS: PC screening, management and bleeding complications were retrospectively investigated at 14 French HTCs between 2003 and 2018.
RESULTS
RESULTS
Among> 1549 > 50-year-old PWHs, 73 (4.7%) underwent PC screening (median age 71.1 years; 67/6 HA/HB, 17/56 severe-moderate/mild). At diagnosis, haematuria was infrequent. Prophylaxis was administered during 76/86 (88%) prostate biopsies (PB) (n = 67 clotting factor concentrates, CFC; n = 9 desmopressin; n = 17 associated with tranexamic acid, TA). Bleeding (11/86, 12.8%) occurred mainly post-prophylaxis (median delay: 7 days): haematuria (9/11, 81.8%), and rectal bleeding (2/11, 18.2%) including one major (1.2%). PC was confirmed in 50/86 PB and in two prostatectomy specimens (total n = 50 patients, n = 6 with only active surveillance). Surgery (n = 28/44 patients) was managed with CFC. Fifteen patients had radiotherapy/brachytherapy, 10 had hormone therapy; CFC-based prophylaxis was only prescribed for brachytherapy (n = 2). Major bleedings occurred in 3/28 (10.7%) and 2/15 (13.3%) patients who underwent surgery and radio/brachytherapy, respectively. No bleeding risk factor was found.
CONCLUSION
CONCLUSIONS
Our data indicate that PB requires prophylaxis for atleast 7 days, using CFC, desmopressin or TA in function of haemophilia severity. PC surgery should be considered at high bleeding risk. Long-term post-procedural CFC or oral TA could be discussed. Radiotherapy/brachytherapy also should be managed with prophylaxis (CFC or TA).
Substances chimiques
Deamino Arginine Vasopressin
ENR1LLB0FP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437-444Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Shapiro S, Makris M. Haemophilia and ageing. Br J Haematol. 2019;184:712-720.
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16-27.
Defossez G, Uhry Z, Delafosse P, et al. Cancer incidence and mortality trends in France over 1990-2018 for solid tumors: the sex gap is narrowing. BMC Cancer. 2021;21:726.
Astermark J, Makris M, Mauser-Bunschoten E, et al. Malignant disease in the haemophilic population: moving towards a management consensus?. Haemophilia. 2012;18:664-671.
Biron-Andreani C, de Moerloose P, D'Oiron R, Chambost H, Schved JF, Hermans C. Cancer detection and management in patients with haemophilia: a retrospective European multicentre study. Haemophilia. 2014;20:78-82.
Lövdahl S, Henriksson KM, Baghaei F, Holmström M, Berntorp E, Astermark J. Malignancies in Swedish persons with haemophilia: a longitudinal registry study. Blood Coagul Fibrinolysis. 2016;27:631-636.
Petros S, Siegemund T, Stolzenburg JU, Siegemund A, Engelmann L. Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B. Haemophilia. 2007;13:677-679.
Lavery HJ, Senaratne P, Gainsburg DM, Samadi DB. Robotic prostatectomy in a patient with hemophilia. Jsls. 2010;14:439-441.
Fogarty PF, Kouides P. How we manage prostate biopsy and prostate cancer therapy in men with haemophilia. Haemophilia. 2012;18:e88-90.
Rogenhofer S, Hauser S, Breuer A, et al. Urological surgery in patients with hemorrhagic bleeding disorders Hemophilia A, Hemophilia B, von Willebrand disease: a retrospective study with matched pairs analysis. World J Urol. 2013;31:703-707.
Hermans C, de Moerloose P, Dolan G. Clinical management of older persons with haemophilia. Crit Rev Oncol Hematol. 2014;89:197-206.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
Merriel SWD, Funston G, Hamilton W. Prostate cancer in primary care. Adv Ther. 2018;35:1285-1294.
Borghesi M, Ahmed H, Nam R, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71:353-365.
Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876-892.
Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26:1-158.
Dell'Atti L, Stefano P, Gaetano C, Carmelo I. Efficacy of a short prophylaxis with tranexamic acid on hemostasis during transrectal prostate biopsy in patients taking oral anti-platelet treatment. J Buon. 2016;21:680-684.
Sørensen B, Auerswald G, Benson G, et al. Rationale for individualizing haemophilia care. Blood Coagul Fibrinolysis. 2015;26:849-857.
Rozet F, Mongiat-Artus P, Hennequin C, et al. French ccAFU guidelines - update 2020-2022: prostate cancer]. Prog Urol. 2020;30:S136-S251.
Boesen L, Nørgaard N, Løgager V, et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: the biparametric MRI for detection of prostate cancer (BIDOC) study. JAMA Netw Open. 2018;1:e180219.
Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. Bmj. 2014;348:g1502. http://doi.org/10.1136/bmj.g1502
Cao L, Yang Z, Qi L, Chen M. Robot-assisted and laparoscopic vs open radical prostatectomy in clinically localized prostate cancer: perioperative, functional, and oncological outcomes: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e15770.
Wallis CJ, Cheung P, Herschorn S, et al. Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer. Br J Cancer. 2015;112:977-982.
Pabinger I, Fries D, Schöchl H, Streif W, Toller W. Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis. Wien Klin Wochenschr. 2017;129:303-316.
Tagliaferri A, Di Perna C, Santoro C, et al. Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost. 2012;10:90-95.
Li J, Jiang Q, Li Q, Zhang Y, Gao L. Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis. Int Urol Nephrol. 2020;52:619-631.
Meunier ME, Neuzillet Y, Radulescu C, et al. Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?. Prog Urol. 2018;28:475-481.